Tumor samples from a single patient with melanoma provided researchers with new information about gene expression profiles that could inform immunotherapy treatments in the future.
ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.
By better understanding the similarities and differences between T-cell receptors, researchers will be better able to develop personalized cancer immunotherapies.
The FDA has approved dabrafenib in combination with trametinib for the treatment of BRAF V600E mutated non-small cell lung cancer.
A novel high-intensity sequencing approach enabled broad detection of genomic variants in plasma with high rates of concordance with corresponding tumor tissue in patients with metastatic breast, lung, and prostate cancer.
Dr. Karen Reckamp talks about ways to incorporate biomarkers for the treatment of lung cancer with immunotherapy into clinical practice at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago.
A prospective phase III validation study found that AZGP1 has significant prognostic utility as a biomarker in localized prostate cancer.
The FDA has approval pembrolizumab (Keytruda), in combination with chemotherapy, for the first-line treatment of patients with metastatic non-squamous non–small-cell lung cancer.
Researchers at Seattle Children's Research Institute announced the first-in-human clinical trial aimed to extend remission for children and young adults with leukemia treated with CAR T-cell immunotherapy.
On April 28, 2017, the US Food and Drug Administration approved midostaurin (Rydapt) for treating newly diagnosed FLT3-mutated acute myeloid leukemia and three types of systemic mastocytosis.